Disseminated cutaneous fusariosis in human immunodeficiency virus-infected patient and dramatic response with oral itraconazole

被引:0
作者
Kumari, Indu [1 ]
Singh, Satyendra Kumar [1 ]
Chauhan, Rishabh Kumar [1 ]
Kaushal, Satyendra Kumar [2 ]
机构
[1] Banaras Hindu Univ, Inst Med Sci, Dept Dermatol & Venereol, Varanasi 221005, Uttar Pradesh, India
[2] Banaras Hindu Univ, Inst Med Sci, Dept Microbiol, Varanasi, Uttar Pradesh, India
关键词
Disseminated; Fusarium; human immunodeficiency virus; itraconazole; AMPHOTERICIN-B; VORICONAZOLE; MANAGEMENT; AGENTS; HOSTS;
D O I
10.4103/ijdvl.IJDVL_360_16
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Fusarium species are known to cause disseminated cutaneous lesions in immunocompromised patients. Some cases of fusariosis are reported in patients infected with the human immunodeficiency virus. There are two reports in such patients with systemic comorbidities like lymphoma, neutropenia and infective port-a-catheter. Another reported patient had systemic fusariosis, without skin involvement. Diagnosis and treatment of cutaneous fusariosis is difficult and resistance to antifungals is a problem. Our patient was at an advanced human immunodeficiency virus infection stage with disseminated cutaneous fusariosis, without any systemic involvement, who responded completely to oral itraconazole.
引用
收藏
页码:362 / 368
页数:7
相关论文
共 16 条
[1]   Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods [J].
Alastruey-Izquierdo, Ana ;
Cuenca-Estrella, Manuel ;
Monzon, Araceli ;
Mellado, Emilia ;
Luis Rodriguez-Tudela, Juan .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (04) :805-809
[2]   Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Nangia, S ;
Rex, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3946-3951
[3]   Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].
Boutati, EI ;
Anaissie, EJ .
BLOOD, 1997, 90 (03) :999-1008
[4]  
Carrillo-Munoz A J, 2001, Rev Esp Quimioter, V14, P281
[5]  
Clinical and Laboratory Standards Institute, 2008, M38A CLSI
[6]   Port-a-cath-related Fusarium oxysporum infection in an HIV-infected patient: Treatment with liposomal amphotericin B [J].
Eljaschewitsch, J ;
Sandfort, J ;
Tintelnot, K ;
Horbach, I ;
Ruf, B .
MYCOSES, 1996, 39 (3-4) :115-119
[7]   Fatal Disseminated Fusarium Infection in a Human Immunodeficiency Virus Positive Patient [J].
Esnakula, Ashwini K. ;
Summers, Irorere ;
Naab, Tammey J. .
CASE REPORTS IN INFECTIOUS DISEASES, 2013, 2013
[8]   In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature [J].
Espinel-Ingroff, A ;
Boyle, K ;
Sheehan, DJ .
MYCOPATHOLOGIA, 2001, 150 (03) :101-115
[9]   Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient [J].
Guarro, J ;
Nucci, M ;
Akiti, T ;
Gené, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3460-3462
[10]   Fusarium spp. as agents of onychomycosis in immunocompetent hosts [J].
Guilhertnetti, Eliana ;
Takahachi, Gisele ;
Shinobu, Cristiane Suerni ;
Estivalet Svidzinski, Terezinha Inez .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2007, 46 (08) :822-826